The European Commission (EC) has granted marketing authorisation for AKANTIOR (polihexanide), the first and only approved treatment for acanthamoeba keratitis (AK) globally, announced Avanzanite Bioscience B.V., a commercial-stage specialty pharmaceutical company. The approval, which applies to both adults and children aged 12 and over, marks a significant milestone for the treatment of this rare and […]
Alexion, a subdivision of AstraZeneca focusing on rare diseases, has announced its definitive purchase and licensing agreement for a portfolio of preclinical gene therapy programmes from Pfizer Inc. The deal, a move to strengthen Alexion and AstraZeneca’s commitment to next-generation genomic medicines, is worth up to $1 billion, plus tiered royalties on sales. This acquisition […]
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a deal worth $68 million. As per the terms of the deal, shareholders of the NASDAQ-listed LogicBio Therapeutics will be paid $2.07 per share by Alexion, AstraZeneca Rare Disease. The latter was formed following last year’s $39 billion […]
Idera Pharmaceuticals, a US-based biopharma company, has acquired Aceragen, a biotechnology company focused on developing drugs for rare, orphan pulmonary, and rheumatic diseases. The acquisition was carried out through an all-stock deal in a ratio under which original Idera Pharmaceuticals’ shareholders will own a stake of around 33% in the combined company, while Aceragen’s shareholders […]
CANbridge Pharmaceuticals said that it has dosed the first patient in a phase 1/2 trial of CAN103 in treatment-naïve patients in China having Gaucher disease (GD) Types I and III. The clinical trial of the recombinant human glucocerebrosidase enzyme replacement therapy is likely to enroll nearly 40 Gaucher disease patients. Gaucher disease is a lysosomal […]
Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline and grow its rare disease medicine portfolio. Viela Bio is focused on developing and commercializing therapies for a wide variety […]
AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. As per the terms of the deal, Alexion Pharmaceuticals’ shareholders will be paid $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca, valuing […]
Pegunigalsidase alfa (PRX–102) update : Protalix BioTherapeutics said that the US Food and Drug Administration (FDA) has extended the prescription drug user fee act (PDUFA) date for review of pegunigalsidase alfa (PRX–102) as a treatment of adults with Fabry disease. The PDUFA action date for reviewing the company’s biologics license application (BLA) has been extended […]
F2G has bagged orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for olorofim (formerly F901318) for the treatments of invasive mold infections – invasive aspergillosis and lomentospora/scedosporium infections, and also the fungal infection – coccidioidomycosis (Valley Fever). For the three infections, there are significant unmet medical needs. In November 2019, F2G […]
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]
